ALKS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Alkermes Plc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 48.99 USD
-7.4% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 28.7% above the Trend Line and sits at 78.1% of its 52-week range. The latest completed week returned -7.4%, after a -10.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is volatility with 51/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: earnings are due in 3d.

Setup score 61 out of 100
Latest Close 48.99 USD 31 Jul 2026
1W Return -7.4% latest completed week
4W Return -10.2% short-term follow-through
12W Return 40.0% quarterly tape
Trend Breadth 59.6% 31 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • The trend backdrop is active with a 18-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 43.38% based on similar historical setup states.
  • 2 reversal markers appear in the recent smart-money tape.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -7.4% Latest completed week; four-week move -10.2%. Indicator stack 78/67 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.38% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 51/100 conviction; expected move 13.5%. News sentiment 56/100 61 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 28.7% above the Trend Line and sits at 78.1% of its 52-week range. The latest completed week returned -7.4%, after a -10.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9912-week average 0.84

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.99Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.2% over four weeks, 40.0% over 12 weeks, and 84.5% over one year. The current trend has remained active for 18 consecutive weeks.

Performance by holding period

1W-7.4%
4W-10.2%
12W40.0%
26W44.6%
52W84.5%
Active trend streak18 weeks
Active weeks in one year31
Trend breadth59.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.08Latest activity-pressure read.
Pressure change-27.0%Four-week change in activity pressure.
Leadership32.10Latest relative-leadership reading.
RS change-31.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength44/100Blend of value, momentum, and quality. Underlying universe rank 57; rank 1 is best.
Value5/100Relative valuation strength. Underlying universe rank 96; rank 1 is best.
Quality81/100Profitability and accounting quality. Underlying universe rank 20; rank 1 is best.
Momentum95/100Medium-term price momentum. Underlying universe rank 6; rank 1 is best.
Growth8/100Revenue and earnings growth. Underlying universe rank 93; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework22/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
57.7x
Price divided by trailing earnings.
Price / sales
5.6x
Market value relative to trailing revenue.
EV / EBITDA
36.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
86.6%
Gross profit retained from each unit of revenue.
Operating margin
15.2%
Operating profit retained from revenue.
Free-cash-flow margin
18.6%
Free cash flow generated from revenue.
Return on invested capital
6.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
3.2%
Latest one-year revenue growth.
EPS growth
-56.7%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-47.4%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.0%
Net share repurchases relative to market value.
Shareholder yield
-0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
4.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ALKS shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.52, expected move of 13.5%, and Sharemaestro trend signal active.

Conviction51/100
Expected move13.5%
Put/call volume0.52
Pressure37
Speculation40
Volatility76
Trend agreement74
Open options detail
Insider activity6 / 14

6 acquisitions and 14 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 61 relevant articles.

22 positive · 34 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move13.5%Nearest-chain priced movement where available.
52-week drawdown-12.0%Distance below the 52-week high.
13-week volatility7.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+22.4%Week of 26 Jun.
Worst week-7.4%Week of 31 Jul.
Latest week-7.4%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains9
Flat weeks0
Modest losses5
Sharp losses6
Recent vol7.6%13-week weekly-return volatility.
Base vol6.2%52-week weekly-return volatility.
Up/down split31/21Count of positive and negative weeks in the 52-week window.
Average skew4.9% / -3.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape63/100

Trend, activity pressure, participation, and risk combine to a 63/100 tape read.

 Indicator analysis87/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.99; 2 reversal markers Next-Week ExpectancyNegative 43.38%

Next-week expectancy is negative with a 43.38% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors55/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 69; Small Cap Core rank 98 SVQF22/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 565.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options56/100

ALKS shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.52, expected move of 13.5%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 13.5% Sentiment56/100

Weighted news tone is neutral across 61 relevant articles.

H.C. Wainwright reiterates Neutral stock rating on Alkermes Insiders6 / 14

6 acquisitions and 14 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202648.99 USD-7.4%38.06 USD30.20 USD1.0832.1012.4MOn
24 Jul 202652.89 USD0.3%37.37 USD30.06 USD1.1944.596.7MOn
17 Jul 202652.72 USD1.5%36.56 USD29.91 USD1.3743.438.5MOn
10 Jul 202651.94 USD-4.8%35.75 USD29.77 USD1.4436.608.5MOn
3 Jul 202654.58 USD-0.9%34.97 USD29.64 USD1.4947.049.2MOn
26 Jun 202655.08 USD22.4%34.13 USD29.48 USD1.5051.0420.2MOn
19 Jun 202644.99 USD1.6%33.28 USD29.33 USD1.4118.9412.4MOn
12 Jun 202644.28 USD3.5%32.74 USD29.25 USD1.2620.439.3MOn
5 Jun 202642.80 USD1.4%32.23 USD29.17 USD1.2019.3010.2MOn
29 May 202642.19 USD14.6%31.90 USD29.10 USD1.0212.3310.6MOn
22 May 202636.80 USD-1.8%31.52 USD29.02 USD0.670.748.1MOn
15 May 202637.48 USD7.1%31.28 USD28.97 USD0.423.5912.7MOn
8 May 202634.99 USD4.8%31.04 USD28.92 USD0.26-3.8813.1MOn
1 May 202633.38 USD0.2%30.92 USD28.90 USD0.21-3.729.1MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.